Currently, Seres Therapeutics Inc [MCRB] is trading at $24.71, up 14.19%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MCRB shares have gain 65.84% over the last week, with a monthly amount glided 33.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Seres Therapeutics Inc [NASDAQ: MCRB] stock has seen the most recent analyst activity on May 08, 2025, when Chardan Capital Markets downgraded its rating to a Neutral but kept the price target unchanged to $6 for it. Previously, JP Morgan downgraded its rating to Underweight on October 24, 2024. JP Morgan started tracking the stock assigning a Neutral rating and suggested a price target of $7 on April 21, 2023. Goldman downgraded its rating to a Sell and reduced its price target to $7 on July 23, 2021. In a note dated March 05, 2021, Chardan Capital Markets upgraded a Buy rating on this stock but restated the target price of $30.
This stock has fluctuated between a low of $6.53 and a high of $24.67 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $1.25 within the next 12 months. Seres Therapeutics Inc [NASDAQ: MCRB] shares were valued at $24.71 at the most recent close of the market. An investor can expect a potential drop of -94.94% based on the average MCRB price forecast.
Analyzing the MCRB fundamentals
Gross Profit Margin for this corporation currently stands at -0.25% with Operating Profit Margin at -16.39%, Pretax Profit Margin comes in at 0.85%, and Net Profit Margin reading is 0.85%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.15 and Total Capital is -0.85. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.05 points at the first support level, and at 15.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.61, and for the 2nd resistance point, it is at 30.51.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Seres Therapeutics Inc [NASDAQ:MCRB] is 2.30. Also, the Quick Ratio is 2.30, while the Cash Ratio stands at 2.12. Considering the valuation of this stock, the price to sales ratio is 638.70, the price to book ratio is 4.96 and price to earnings (TTM) ratio is 40.70.
Transactions by insiders
Recent insider trading involved Young Teresa L., that happened on Nov 15 ’25 when 1042.0 shares were sold. Director, Shaff Eric D. completed a deal on Nov 15 ’25 to sell 217.0 shares. Meanwhile, DesRosier Thomas sold 76.0 shares on Nov 15 ’25.
